Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUPICAS: DL-3-n-butylphthalide for prevention of ischemic cerebrovascular events in intracranial atherosclerotic stenosis
ChiCTR2500104739Phase 4Not yet recruiting
- Sponsor
- PrecisionLife
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of butylphthalide in intracranial stenosis, ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by PrecisionLife. Primary endpoint: Cerebral ischemic events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
butylphthalide
03
Conditions
intracranial stenosisischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2500104739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104739.